T-Cell therapy Market By Therapy Type (CAR T-Cell therapy, T-Cell Receptor (TCR)-Based), By Indication (Lymphoma, Acute Lymphocytic Leukemia, Others), By End User (Hospitals, Cancer Treatment Centers): Global Opportunity Analysis and Industry Forecast, 20

T-Cell therapy Market By Therapy Type (CAR T-Cell therapy, T-Cell Receptor (TCR)-Based), By Indication (Lymphoma, Acute Lymphocytic Leukemia, Others), By End User (Hospitals, Cancer Treatment Centers): Global Opportunity Analysis and Industry Forecast, 2023-2032

The T-cell therapy Market valued for $2,823.07 million in 2022 and is estimated to reach $15,182.30 million by 2032, exhibiting a CAGR of 18.3% from 2023 to 2032. T cells are a type of immune cell that plays a critical role in the body's defense against disease. T-cell therapy involves the manipulation of a patient's T cells outside the body, often using genetic engineering techniques, to enhance their ability to recognize and attack cancer cells or other disease-causing cells. These modified T cells are then infused back into the patient's body, where they can seek out and destroy cancer cells. 

The T-cell therapy market is being driven by several key factors such as the increasing prevalence of cancer resulting in a greater demand for effective treatment options. T-cell therapy has emerged as a promising approach for treating cancer and other diseases including autoimmune disorders and viral infections, driving its adoption and growth. Additionally, the aging population is another factor that is driving the demand for T-cell therapies. The geriatric population is more prone to developing cancer and other diseases, creating a larger pool of potential patients for T-cell therapy. Furthermore, advances in biotechnology and genetic engineering have made it possible to develop more targeted and personalized T-cell therapies, which are likely to drive the market growth. These therapies have shown promising results in clinical trials, leading to increased investment in research and development activities. 

Moreover, the rise in key strategies adopted by the key market players such as agreement, and collaborations further drives the growth of the market during the forecast period. For instance, on February 10, 2021, AbbVie and Caribou Biosciences, Inc., a leading clinical-stage CRISPR genome editing biotechnology company, entered into a collaboration and license agreement for the research and development of chimeric antigen receptor (CAR)-T cell therapeutics. Furthermore, a rise in approvals from regulatory organizations is further providing opportunity for market growth. For instance, on October 17, 2022, Gilead Company, a biopharmaceutical company received the European Commission (EC) approval for the use of Yescarta (axicabtagene ciloleucel) for the treatment of adult patients with diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) who relapse within 12 months from completion of, or are refractory to, first line chemoimmunotherapy.  Thus, the adoption of such strategies by key manufacturers can potentially increase the demand and adoption of cell therapy technology and provide lucrative opportunity to market growth. 

However, side effects associated with cellular therapies such as cytokine release syndrome and neurotoxicity, which can limit its use. Furthermore, the high cost of treatment is also a significant challenge for patients and healthcare providers and can limit the adoption of these therapies. These factors collectively have hindered the market growth to some extent.  

The global T-cell therapy market is segmented into therapy type, indication, end user and region. As per therapy type, the market is categorized into CAR T-cell Therapy and T Cell Receptor (TCR)-Based. The CAR T-cell Therapy segment is further categorized by product type into Axicabtagene Ciloleucel, Tisagenlecleucel, Bexucabtagene Autoleucel and Others (Ciltacabtagene autoleucel, Lisocabtagene Maraleucel, Idecabtagene Vicleucel). According to indication, the market is segregated into Lymphoma, Acute Lymphocytic Leukemia, and Others (Multiple Myeloma, Melanoma). According to end user, the market is segregated into Hospitals and Cancer Treatment Centers. Region wise, the market is analyzed across North America (the U.S., Canada), Europe (Germany, France, the UK, and rest of Europe), Asia-Pacific (Japan, China and rest of Asia-Pacific), and LAMEA (Latin America, Middle East & Africa). 

Major key players that operate in the global T-cell therapy market are Novartis AG, Autolus Therapeutics, Caribou Biosciences, Inc, Gilead Sciences, Immunocore Ltd., Celyad Oncology, Cartesian Therapeutics, Inc., Johnson & Johnson, Bristol-Myers Squibb Company and Cellectis, Inc. The key players operating in the market have adopted product approval, agreement, and collaboration as their key strategies to expand their product portfolio.

Key Benefits For Stakeholders

This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the t-cell therapy market analysis from 2022 to 2032 to identify the prevailing t-cell therapy market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the t-cell therapy market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global t-cell therapy market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Therapy Type

CAR T-Cell therapy
Product Type
Axicabtagene Ciloleucel
Tisagenlecleucel
Brexucabtagene Autoleucel
Others
T-Cell Receptor (TCR)-Based

By Indication

Lymphoma
Acute Lymphocytic Leukemia
Others

By End User

Hospitals
Cancer Treatment Centers

By Region

North America
U.S.
Canada
Europe
Germany
France
UK
Rest of Europe
Asia-Pacific
Japan
China
Rest of Asia-Pacific
LAMEA
Latin America
Middle East And Africa
Key Market Players
Caribou Biosciences, Inc
Celyad Oncology
Gilead Sciences, Inc.
Novartis AG
Cellectis, Inc.
Johnson & Johnson
Autolus Therapeutics
Bristol-Myers Squibb Company
Immunocore Ltd.
Cartesian Therapeutics, Inc.

Please Note: It will take 7-10 business days to complete the report upon order confirmation.